Organon launches as new global women’s health company.

Recognizing the need to listen to and act on women’s experiences to address the challenges in women’s health, Organon gathered voices from around the world to create the “Wall of Voices,” a multimedia installation outside of the NYSE. Organon is committed to women’s everyday health needs, with a focus on reproductive health, health issues that are unique to women, as well as conditions that disproportionately affect women. At launch, Organon’s portfolio will consist of more than 60 medicines and products across an international footprint that serves people in more than 140 markets, with nearly 80% of its approximately $6.5 billion in annual revenue generated outside the U.S. Organon believes it is well positioned for organic low-to-mid-single digit growth from its 2021 base of business. Organon has three core pillars that will benefit from renewed management focus and commercial investment: i. Women’s Health: Anchored by Nexplanon (etonogestrel implant), a long-acting reversible contraception, along with its contraceptive and fertility businesses and boosted by its recently announced proposed acquisition of Alydia Health, a medical device company focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding. ii. Biosimilars: A key growth pillar with products available in various parts of the world including Renflexis (infliximab-abda) and Brenzys (etanercept) in immunology and Ontruzant (trastuzumab-dttb) in oncology. Organon’s expertise is in the commercialization of these products, bringing them to more people around the world. iii. Established Brands: 49 well-known products in the respiratory, cardiovascular, dermatology and non-opioid pain areas.